Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study.

Laura G. Estévez,José Luis Fortes,Encarna Adrover,Gloria Peiró,Mireia Margeli,Eva Castellà,José Miguel Cuevas,Laia Bernet,Miguel Ángel Seguí,Xavier Andreu

Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study.

2009

Laura G. Estévez
José Luis Fortes
Encarna Adrover
Gloria Peiró
Mireia Margeli
Eva Castellà
José Miguel Cuevas
Laia Bernet
Miguel Ángel Seguí
Xavier Andreu

Introduction To evaluate the sequential administration of doxorubicin (A) and cyclophosphamide (C) followed by weekly docetaxel in women with stage II to IIIA breast cancer.

Keywords:

General surgery
Taxane
Phases of clinical research
Breast cancer
Doxorubicin
Breast-conserving surgery
Anthracycline
Cyclophosphamide
Docetaxel
Medicine
breast carcinoma
Oncology
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations